Purpose The purpose of the study was to assess the feasibility of quantifying long-term trends in breast tumor DNA copy number variation (CNV) profiles. Methods We evaluated CNV profiles in formalin-fixed paraffin-embedded (FFPE) tumor specimens from 30 randomly selected Kaiser Permanente Northern California health plan women members diagnosed with breast cancer from 1950 to 2010. Assays were conducted for five cases per decade who had available tumor blocks and pathology reports.
During the past decade, new assays for DNA copy number variations (CNVs) have yielded novel information critical both for guiding disease treatment and understanding etiology, given that evidence indicates some CNVs may be caused by environmental exposures [1] [2] [3] . In the case of breast cancer, research indicates that both histologic type and molecular phenotype are associated with genetic alterations-variously involving amplification, translocation, and deletion-of several genes, including MYC, CCND1, HER2, TOP2A, PIK3CA, PRNC1, DBC1, DEC1, TSPAN1, EGFR, ESR1, and EMSY l [4] [5] [6] [7] [8] [9] . These breast cancer CNVs have been shown to be prognostic for survival, recurrence, and metastasis, and predictive of response to treatment [4] [5] [6] , independent of estrogen receptor status [4, 5] , and BRCA1 and BRCA2 status [6] .
From an epidemiologic perspective, it is intriguing to consider evaluation of CNVs in breast cancer tissue over time, as they may result from important time-period-dependent etiologic exogenous exposures. If current population distributions of CNVs differ from those observed in prior decades, this may help inform investigations into specific etiologic exogenous exposures [10] [11] [12] . Attesting to the value of re-analyzing older specimens, a study of Norwegian women born between 1886 and 1977 compared breast cancer incidence rates by molecular subtypes, using re-analyzed specimens, for women born between 1886-1928 and 1929-1977 , and observed evidence of a secular increase, among women ages 50 to 69 at diagnosis, solely for the Luminal A and Luminal B (HER2-) subtypes [13] .
Limited data on time-trends in tumor CNVs, however, exist. One reason is that assays suitable for use in largescale population-based studies have only recently been developed [1] [2] [3] ; a second is the paucity of data about whether such assays can be used on archival formalin-fixed paraffin-embedded (FFPE) tumor specimens [11, 12] . Only one published investigation has, to our knowledge, investigated the use of CNV assays on FFPE specimens older than 15 years [14] ; this study used the leading CNV assay (OncoScan® CNV FFPE Assay [15] ) and reported successfully conducting assays on FFPE specimens up to 28 years old, equivalent to the mid-1980s [14] . One other study, performed with specimens dating 12 years back, found equivalent DNA expression based on fresh frozen versus FFPE tumor specimens [16] . To the best of our knowledge, no studies have assessed use of a CNV assay on specimens that pre-date the mid-1980s.
In this investigation, we accordingly built on our prior study to locate decades-old population-based archival FFPE tumor specimens, spanning from 1950 to 2010 [11] . This prior work was designed to assess the feasibility of retrieving old FFPE specimens and analyzing their tumor profiles using immunostains for clinically relevant biomarkers; key findings were the high rate of successful retrieval of linked pathology reports and specimens (83% of 60 randomly selected breast cancer cases) and the high quality and reliability of the assays [11] . In the current study, we sought to assess both the quality of results and time required to use a CNV assay on these previously retrieved breast cancer tumor specimens. Our a priori hypothesis was that the CNV assay would be equally valid to use, given the well-known stability of DNA preserved even in harsh environments, e.g., forensic and paleoarcheological specimens [17] .
Methods
As previously described [11] , we analyzed FFPE specimens obtained from randomly selected women diagnosed with invasive breast cancer who were the members of Kaiser Permanente, Northern California (KPNC) (IRB approval: Harvard School of Public Health, # CR-20929-02; KPNC, # CN-13LHabe-03-H). Established as an integrated health care delivery system in the 1940s for workers employed in World War II shipyards [18] , KPNC's membership has, since inception, mirrored the economic and racial/ethnic diversity of San Francisco and California's Central Valley [19] . Its cancer registry extends back to cases diagnosed in 1947 [20] .
Between 1947 and 2009, 60,904 breast cancer cases were diagnosed and included in the KPNC cancer registry, of which 7,150 met our feasibility study's eligibility criteria: women who were 50-64 years old at diagnosis and had an invasive tumor ≥ 1 cm. We randomly selected 10 eligible cases per each of 6 time periods (hereafter referred to as decades: 1947-1959, 1960-1969,..., 2000-2009) , and used information available as of 1987 to restrict sampling to cases with lymph node-positive tumors. Among the 60 randomly selected cases (10 per decade), 50 cases had locatable eligible blocks containing tumor tissue. From these 50 cases, we selected a random sample of five cases per decade (total n = 30) for biomarker immunohistochemical analysis [11] , which comprise the same cases used for the CNV assays.
For this study, DNA was extracted from the tumor specimens at the Molecular Epidemiology Research Laboratory at the Beth Israel Deaconess Medical Center. Using a randomly assigned ID number that could be linked back to the tumor data only by the study team, we shipped the tumor DNA to Affymetrix, which employed its OncoScan® CNV FFPE assay [15] . The Affymetrix Lab was blinded to all information about the tumor, including the date of each specimen.
Briefly stated, the OncoScan® CNV FFPE Assay [15] uses molecular inversion probes (MIPs) to provide integrated whole genome copy number alteration and copy-neutral loss of heterozygosity (LOH) data for more than 335,000 markers across the genome, including approximately 900 cancerassociated genes. The assay provides copy number data in both log2 scale as well as linear copy number calls, and for quality assessment, it also provides the sample 2-point relative standard error (2p-RSE), which "takes the median of the relative standard error of a whole genome pairwise comparison and uses the median value to avoid counting abnormal breakpoints that are frequently detected in tumor specimens" [14] . The quality of results and how long it took to interpret the assay data were assessed blind to the date of each tumor specimen. Once the data analysis was completed, the data were incorporated into a table that grouped the tumors by diagnostic date, allowing for calculation of average values for the five tumors per decade.
For data analysis and visualization, we employed the OncoScan™ Nexus Express Software [21] . To investigate and compare CNV profiles of samples in different decades, we used CNV and B-allele frequency (BAF) results of all samples presented by this software [22] . In general, this software uses information from the OncoScan Consol software that obtains data from scanned arrays (stored in CEL files), normalizes the data, performs quality control (QC) checks, determines CNV segments, calculates BAF, and detects LOH.
To assess the feasibility of capturing CNV profiles for specimens from different decades, we focused on general characteristics of the assays' outcome and CNV profiles. We considered QC metrics as the main characteristics of the assay. We also investigated the number and length of CNV events captured by the assay, number of captured CNV genes, and the percentage of published high frequency CNV genes in cancer captured by the assay for all samples.
In addition, we measured extra time required to validate reported CNV results by eye inspection of captured CNV events for each assay.
To validate a CNV segment and its copy number, especially for assays with low QC metrics, it is necessary to study together the allele frequency (BAF) data and log2 ratio data of each CNV event. For QC checks, we used median absolute pairwise difference of log2 ratios (MAPD) and SNP QC of normal diploid markers (ndSNPQC) metrics. The MAPD metric compares the log2 ratios of each adjacent pair of probes and reflects noisiness of log2 ratios. The lower this value the greater the quality of CNV detection. The ndSNPQC metric estimates distances between each genotype (AA, AB, and BB genotype calls), and reflects the separation of the homozygous and heterozygous alleles. The higher the ndSNPQC, the better identification of each genotype and better BAF results. We used MAPD ≤ 0.3 and ndSNPQC ≥ 26 to call high-quality assays, as recommended by Affymetrix [15, 21] .
To investigate the ability of capturing CNV events from specimens belonging to different decades, we compared the number and length of CNV events on average across the time blocks (decades). First, we performed eye inspection to validate the CNV segments; then we used a threshold of 0.2 to filter out non-amplified CNV segments and to call amplified segments and a threshold of − 0.2 to filter out non-deleted CNV segments and to call deleted segments. To investigate the biological and functional relevance and meaningfulness of the captured CNV segments, we annotated the CNV segments to obtain CNV genes, and calculated how many of the identified CNV genes were among published high frequency CNV genes. We used the data published by Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) for obtaining high frequency CNV genes. The METABRIC dataset includes CNV profiles derived from more than 2,000 breast tumors. These tumors have been collected from participants of the METABRIC trial [23] . The METABRIC data are also available through cBioPortal website (http://www.cbiop ortal .org/study ?id=brca_metab ric#summa ry). This dataset provides the frequencies of deletion, amplification, and high-amplification of all genes across all the samples in the METABRIC study. We considered genes with deletion, amplification, and high-amplification frequency greater than 5% as high frequency CNV genes.
Results
As previously reported [11] , we were able to locate pathology reports for 55 cases (92%) among the original random sample of 60 selected cases, and 50 of these cases (83% of the 60) had blocks that contained tumor tissue. From these 50 cases, we selected a random sample of five cases per decade, yielding 30 cases, all of which displayed excellent morphology [11] . Table 1 provides key data on the tumor characteristics and the assay outcomes. All 30 cases yielded sufficient DNA (> 75 ng) for analysis using the OncoScan™ assay. Among these cases, all five specimens from the 1950s failed both the MAPD QC and ndSNPQC tests, as did four of the five specimens from the 1960s, and two of the specimens from the 1970s. By contrast, only one out of the five specimens respectively from the most recent three decades (1980s-2000s) failed the MAPD QC test, and only one out of the five specimens from the most recent two decades (1990s-2000s) failed the ndSNPQC QC test.
With regard to the number of detected CNV segments, notably fewer CNV events after filtering were detected for the specimens from the 1950s to 1960s (average number 30. 8 The earlier specimens also were much more likely to have a lower percentage of high frequency CNV genes (Table 1 ). Among at least one out of the five cases per 
Discussion
Our results indicate assays conducted in the mid-2010s for CNVs may be feasible for FFPE tumor specimens dating back to the 1980s, but less feasible for older specimens. By contrast, specimens pre-dating 1980 (i.e., older than 30 years) would require more assays and more resources to yield interpretable results.
Supporting our interpretation of the study results are two key findings. First, the data presented provide novel empirical evidence that many relevant CNV genes were not being captured from the older specimens (1950s-1960s) . This phenomenon may potentially be due to degradation of DNA from the older samples.
Second, the results demonstrate that the extra evaluation time required for the older specimens was directly related to the assay quality. Stated briefly, the relationship between evaluation time and assay time is as follows: For assays with high QC metric where the data are less noisy and the separation between the genotypes is clear, there is no need for inspection of the detected CNV segments, and the CNV data can be used as reported. However, for assays with marginal or low QC metric, the detected CNV segments need to be validated by eye inspection and adjustment to the software parameters needs to be applied to avoid false positives. Although this extra validation time could potentially be feasible (in terms of time and resources required) for studies with a manageable number of samples, it would be less feasible (and costlier) for large studies with thousands of samples.
The main limitation of our study is small numbers, but this limitation is offset by our ability to analyze a populationbased random sample of tumors extending back five decades (1950s-2000s). Another limitation is a focus solely on breast cancer tumor specimens. However, a recent validation study of the OncoScan® CNV FFPE Assay found comparable performance for "76 FFPE tumor specimens of diverse tissue origin, including breast (n = 28), brain (n = 12), colon (n = 12), lung (n = 11), skin (n = 4), endometrium (n = 2), gastric (n = 2), and others (n = 5)"; no data were provided regarding the years in which the biopsy specimens were obtained [24] . It is also unlikely that problems with the conduct of the assay affected our study results, since the assays were performed by Affymetrix, the company that developed the OncoScan™ [15] , and Affymetrix conducted the assays blinded to any information about the tumor specimens, including their date. Factors affecting specimen quality, as related to the age of the specimens, rather than the conduct of the assays, are thus the most plausible explanation for the difference in results for the older versus more recent specimens. Whether our results can be generalized to other older specimens is also unknown, since all specimens were from a single institution, and pre-analytic variables (e.g., ischemia time, type of fixative, and time of fixation) that could affect assay results potentially could vary across institutions. Additional evidence supporting analysis of tumor specimens up to three decades old is provided by a study of breast cancer tumor FFPE specimens obtained from 1,212 women diagnosed between 1985 and 2000. Among these cases, 56 specimens (4.6%) had insufficient DNA for tumor extraction, 153 (12.6%) had DNA extraction failure, and 32 (2.6%) had MIP assay failure, and among the 81.2% of specimens successfully analyzed, 95% passed the 2p-RSE threshold [5] . These findings, in conjunction with our results, support the use of a DNA CNV assay on tumor specimens dating back to the mid-1980s. Our findings, however, did not provide support for our a priori hypothesis that a DNA-based assay would be robust to specimen age (over a period of 50 years) and instead raise cautions for any study that seeks to analyze specimens from earlier time periods, i.e., dating back to before 1980, and hence more than 30 years old at the time of the assay.
Our results suggest two new avenues for research. First, future studies should explore whether the difficulties we encountered with analyzing tumors from cases diagnosed before the 1980s was a reflection of the time period during which the tumors were preserved, versus the actual age of the specimen at the time the assay was conducted, or both. Second, future studies could include a similar evaluation of samples from other tumor sites to determine consistency of findings across tumor types as another validation of the methods used in the work presented here. In light of the importance of tumor CNVs for treatment modality choice [4] [5] [6] [7] and etiology [1-3, 8, 9] , more research is warranted on methods for analyzing the unique resource of archival FFPE specimens [11, 12] .
